Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Achieve Life Sciences Inc (NQ: ACHV )

9.000 USD +0.070 (+0.78%)
Streaming Delayed Price Updated: 2:37 PM EST, Nov 25, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,777
Open 8.800
Bid (Size) 8.960 (1)
Ask (Size) 9.000 (2)
Prev. Close 8.930
Today's Range 8.800 - 9.250
52wk Range 0.2300 - 18.26
Shares Outstanding 2,764,276
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine... 
From PR Newswire
Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine... 
From PR Newswire

Performance

YTD
+1630.77%
+1630.77%
1 Month
+7.66%
+7.66%
3 Month
+4.53%
+4.53%
6 Month
+2043.37%
+2043.37%
1 Year
+870.35%
+870.35%

More News

Read More
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020
From PR Newswire
Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020
From ACCESSWIRE
Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
From PR Newswire
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
From PR Newswire
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (vareniclin
From PR Newswire
Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study
From PR Newswire
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference
From PR Newswire
Achieve Life Sciences to Present at Upcoming Investor Conferences
From PR Newswire
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.